Zevra Therapeutics (ZVRA) 10-Q 14 May 19 2019 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 13, 2019
Document Information [Line Items]
Entity Registrant Name	KEMPHARM, INC
Entity Central Index Key	0001434647
Trading Symbol	kmph
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		28,519,259
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Balance Sheets (Curre

Condensed Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Assets
Cash and cash equivalents	$ 13,438	$ 18,409
Marketable securities		3,260
Prepaid expenses and other current assets	1,873	2,052
Total current assets	15,311	23,721
Property and equipment, net	1,688	1,753
Operating lease right-of-use assets	1,785
Restricted cash	528	710
Other long-term assets	555	562
Total assets	19,867	26,746
Liabilities and stockholders' deficit
Accounts payable and accrued expenses	8,178	8,342
Current portion of convertible notes	6,370	3,333
Current portion of capital lease obligation		214
Current portion of operating lease liabilities	395
Other current liabilities	229	115
Total current liabilities	15,172	12,004
Convertible notes, less current portion, net	75,373	78,105
Derivative and warrant liability	1,665	2,118
Capital lease obligation, less current portion		396
Operating lease liabilities, less current portion	2,142
Other long-term liabilities	351	689
Total liabilities	94,703	93,312
Commitments and contingencies (Note D)
Stockholders’ deficit:
Common stock, $0.0001 par value, 250,000,000 shares authorized, 27,976,823 shares issued and outstanding as of March 31, 2019 (unaudited); 26,455,352 shares issued and outstanding as of December 31, 2018	3	3
Additional paid-in capital	158,644	154,623
Accumulated deficit	(233,483)	(221,192)
Total stockholders' deficit	(74,836)	(66,566)
Total liabilities and stockholders' deficit	19,867	26,746
Series A Convertible Preferred Stock [Member]
Stockholders’ deficit:
Preferred stock
Undesignated Preferred Stock [Member]
Stockholders’ deficit:
Preferred stock

Condensed Balance Sheets (Cur_2

Condensed Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Preferred stock, shares authorized (in shares)	10,000,000
Preferred stock, shares issued (in shares)	9,577
Preferred stock, shares outstanding (in shares)	3,337	3,337
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	250,000,000	250,000,000
Common stock, shares issued (in shares)	27,976,823	26,455,352
Common stock, shares outstanding (in shares)	27,976,823	26,455,352
Series A Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	9,578	0
Preferred stock, shares issued (in shares)	9,577	0
Preferred stock, shares outstanding (in shares)	3,337	0
Undesignated Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	9,990,422	9,990,422
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0

Unaudited Condensed Statements

Unaudited Condensed Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenue
Operating expenses:
Research and development	8,531	11,637
General and administrative	2,838	3,132
Total operating expenses	11,369	14,769
Loss from operations	(11,369)	(14,769)
Other (expense) income:
Interest expense related to amortization of debt issuance costs and discount	(305)	(390)
Interest expense on principal	(1,229)	(1,442)
Fair value adjustment related to derivative and warrant liability	453	(9,741)
Interest and other income, net	151	115
Total other (expense) income	(930)	(11,458)
Loss before income taxes	(12,299)	(26,227)
Income tax benefit	8	8
Net loss	$ (12,291)	$ (26,219)
Net loss per share:
Basic and diluted (in dollars per share)	$ (0.46)	$ (1.77)
Weighted average number of shares of common stock outstanding:
Basic and diluted (in shares)	26,701,891	14,791,882

Unaudited Condensed Statement o

Unaudited Condensed Statement of Changes in Stockholders' Deficit - USD ($) $ in Thousands	Purchase Agreement [Member]Series A Convertible Preferred Stock [Member]	Purchase Agreement [Member]Undesignated Preferred Stock [Member]	Purchase Agreement [Member]Common Stock [Member]	Purchase Agreement [Member]Additional Paid-in Capital [Member]	Purchase Agreement [Member]Retained Earnings [Member]	Purchase Agreement [Member]	Series A Convertible Preferred Stock [Member]	Undesignated Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2017									$ 1	$ 107,209	$ (164,726)	$ (57,516)
Net loss											(26,219)	(26,219)
Stock-based compensation expense										1,281		1,281
Issuance of common stock in connection with ATM, net of commissions			$ 1	$ 2,797		$ 2,798
Offering expenses charged to equity										(27)		(27)
Balance at Mar. 31, 2018									2	111,260	(190,945)	(79,683)
Balance at Dec. 31, 2018									3	154,623	(221,192)	(66,566)
Net loss											(12,291)	(12,291)
Stock-based compensation expense										1,290		1,290
Issuance of common stock in connection with ATM, net of commissions				$ 2,721		$ 2,721
Offering expenses charged to equity										10		10
Balance at Mar. 31, 2019									$ 3	$ 158,644	$ (233,483)	$ (74,836)

Unaudited Condensed Statement_2

Unaudited Condensed Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net loss	$ (12,291)	$ (26,219)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	1,290	1,281
Non-cash interest expense	863	1,031
Amortization of debt issuance costs and debt discount	305	390
Depreciation and amortization expense	78	83
Fair value adjustment related to derivative and warrant liability	(453)	9,741
Write-off of deferred offering costs	10
Change in assets and liabilities:
Prepaid expenses and other assets	186	(1,650)
Operating lease right-of-use assets	(1,785)
Accounts payable and accrued expenses	(1,027)	1,268
Operating lease liabilities	2,537
Other liabilities	(779)	(24)
Net cash used in operating activities	(11,066)	(14,099)
Cash flows from investing activities:
Purchases of property and equipment	(17)
Maturities of marketable securities	3,260	9,229
Net cash provided by investing activities	3,243	9,229
Cash flows from financing activities:
Proceeds from equity line of credit	2,721
Proceeds from at-the-market offering, net of commissions		2,798
Repayment of obligations under capital lease		(49)
Repayment of principal on finance lease liabilities	(51)
Net cash provided by financing activities	2,670	2,749
Net decrease in cash, cash equivalents and restricted cash	(5,153)	(2,121)
Cash, cash equivalents and restricted cash, beginning of period	19,119	11,971
Cash, cash equivalents and restricted cash, end of period	13,966	9,850
Supplemental cash flow information:
Cash paid for interest	2,287	2,618
Deferred offering costs included in accounts payable and accrued expenses	105
Trade date receivables		1,511
Property and equipment included in accounts payable and accrued expenses		$ 3

Note A - Description of Busines

Note A - Description of Business and Basis of Presentation	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	A. Description of Business and Basis of Presentation Organization KemPharm, Inc. (the “Company”) is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary Ligand Activated Therapy ("LAT™") technology. The Company utilizes its proprietary LAT technology to generate improved prodrug versions of U.S. Food and Drug Administration (the "FDA") approved drugs as well as to generate prodrug versions of existing compounds that may KP415 KP484, KP879. October 2006 May 2014. The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for inter im financial information and with the instructions to Form 10 8 03 X. not three March 31, 2019 not may December 31, 2019. This interim information should be read in conjunction with the audited financial statements included in the Company ’s Annual Report on Form 10 December 31, 2018, March 1, 2019 (the "Annual Report"). Going Concern The unaudited condensed financial statements have been prepared on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. The Company has experienced recurring losses from operations and negative operating cash flows and has a stockholders' deficit, and its existing cash and cash equivalents and restricted cash are not one may may may not Management believes these conditions raise substantial doubt about the Company’s ability to continue as a going concern within the twelve not Management intends to finance operating costs over the next twelve 3 $150.0 I.B.6. 3, may twelve twelve I.B.6. may not one third 60 I.B.6. 3 12 $18.5 $15.3 $3.2 3 twelve may March 31, 2019, 1,401,271 $2.7 no Entry into First ATM Agreement In October 2016, September 2018. 762,338 $4.9 three 3.0% Entry into Second ATM Agreement In September 2018, may $50,000,000 3 October 17, 2016. 3 $50,000,000 March 2019, $3.2 I.B.6 3. March 31, 2019, not RBCCM may 415 1933, may three 3.0% The Company is not Underwritten Public Offering In October 2018, October 10, 2018, 8,333,334 3, October 17, 2016, October 17, 2016 October 5, 2018, $3.00 $23.1 Entry into Purchase Agreement In February 2019, may $15.0 36 120,200 may 3 March 31, 2019, 1,401,271 $2.7

Note B - Summary of Significant

Note B - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	B. Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its estimates, including those related to the useful lives of property and equipment, and assumptions used for purposes of determining stock-based compensation, income taxes, and the fair value of the derivative and warrant liability, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities. Application of New or Revised Accounting Standards—Adopted From time to time, the Financial Accounting Standards Board (the “FASB”) or other standard-setting bodies issue accounting standards that are adopted by the Company as of the specified effective date. In April 2012, not In February 2016, 2016 02, Leases (Topic 842 ) 2016 02” January 1, 2019 not 12 not 2016 02 $2.6 January 1, 2019. In July 2017, 2017 11, Earnings Per Share (Topic 260 ), Distinguishing Liabilities from Equity (Topic 480 ), Derivatives and Hedging (Topic 815 ) – I. Accounting for Certain Financial Instruments with Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception 2017 11" 480 260. December 15, 2018, 2017 11 not In June 2018, 2018 07, Compensation – Stock Compensation (Topic 820 2018 07" 718, December 15, 2018, 718 718 718 2018 07 not Application of New or Revised Accounting Standards —Not In August 2018, 2018 13, Fair Value Measurement (Topic 820 2018 13" 820, Conceptual Framework for Financial Reporting—Chapter 8: August 28, 2018, December 15, 2019, 3 2018 13

Note C - Debt Obligations

Note C - Debt Obligations	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	C. Debt Obligations Deerfield Facility Agreement In June 2014, $60 first $15 $10 June 30, 2016, no 9.75% may $5.85 The Company also issued to Deerfield a warrant to purchase 14,423,076 $0.78 June 2, 2024 1,923,077 $5.85 260, Earnings per Share, may one third 12 1934, In addition, the Company issued to Deerfield 1,923,077 256,410 $1.5 Pursuant to the Deerfield Facility Agreement, the Company may not $750,000 The Company must repay one third fourth fifth February 14, 2020. February 2016. The outstanding principal amount due on the fourth anniversary of the Deerfield Facility Agreement and the related accrued but unpaid interest as of such date was converted in common stock of the Company in accordance with the provisions of the Deerfield Convertible Note, as amended. Refer to the section entitled Facility Agreement Waiver and Fifth Amendment to Senior Secured Convertible Note below. Interest accrued on outstanding debt under the Deerfield Facility Agreement is due quarterly in arrears. Upon notice to Deerfield, the Company had the option to have one first eight July 1, 2016. eight June 30, 2016. July 1, 2016. First Amendment to Facility Agreement, Senior Secured Convertible Note and Warrant In connection with the IPO, in March 2015, Second Amendment to Senior Secured Convertible Note and Warrant In January 2016, Issuance of 5.50% Senior Convertible Notes and Third Amendment to Facility Agreement, Senior Secured Convertible Note and Warrant In February 2016, $86.3 5.50% 2021 “2021 2021 144A The net proceeds from the Note Offering were approximately $82.8 $18.6 The 2021 February 9, 2016 2021 February 1 August 1 August 1, 2016, 5.50% 2021 February 1, 2021 2021 not no 2021 The 2021 58.4454 $1,000 2021 $17.11 2021 not 2021 If the Company undergoes a “fundamental change” (as defined in the Indenture), holders may 2021 100% 2021 2021 one 2021 may The Indenture includes customary terms and covenants, including certain events of default after which the 2021 may In connection with the Note Offering, in February 2016, 2021 Refer to the section entitled Exchange Agreement below for a further discussion of an exchange of a certain portion of the 2021 $0.0001 Fourth Amendment to Senior Secured Convertible Note and Warrant In connection with entering into the First ATM Agreement, in October 2016, 415 Facility Agreement Waiver and Fifth Amendment to Senior Secured Convertible Note In June 2018, $3,333,333 $168,288 598,568 June 2, 2018; ( Exchange Agreement In October 2018, $9,577,000 2021 9,577 $95,105 $25,000 As a condition to closing of the Exchange Agreement, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State Delaware, setting forth the preferences, rights and limitations of the Series A Preferred Stock. Each share of Series A Preferred Stock has an aggregate stated value of $1,000 $3.00 3,192,334 4.985% not $0.0001 not not not First Supplemental Indenture, Sixth Amendment to Deerfield Convertible Note and Fifth Amendment to Deerfield Warrant In November 2018, 2021 not 9.985% three 3 may Also in November 2018, 4.985% 2021 4.985%. Seventh Amendment to Deerfield Convertible Note and Sixth Amendment to Deerfield Warrant In February 2019, not may Except as modified by the First Amendment, Second Amendment, Third Amendment, Fourth Amendment, Fifth Amendment, Sixth Amendment and Seventh Amendment, all terms and conditions of the Deerfield Facility Agreement, Deerfield Warrant and Deerfield Convertible Note remained in full force and effect. Line of Credit During the second 2016, $1.1 January 31, 2018. January 31, 2018, January 31, 2020. March 2019, .

Note D - Commitments and Contin

Note D - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	D. Commitments and Contingencies From time to time, the Company is involved in various legal proceedings arising in the normal course of business. For some matters, a liability is not not March 31, 2019 December 31, 2018, no

Note E - Preferred Stock and Wa

Note E - Preferred Stock and Warrants	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Preferred Stock [Text Block]	E. Preferred Stock and Warrants Authorized, Issued, and Outstanding Preferred Stock As of March 31, 2019, 10,000,000 9,578 9,577 December 31, 2018 3,337 December 31, 2018 March 31, 2019. In October 2018, 9,577 $1,000 $3.00 3,192,334 4.985% not $0.0001 not not not March 31, 2019, 6,240 2,080,000 As of March 31, 2019, 3,337 1,112,334

Note F - Common Stock and Warra

Note F - Common Stock and Warrants	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	F. Common Stock and Warrants Authorized, Issued, and Outstanding Common Shares As of March 31, 2019 December 31, 2018, 250,000,000 27,976,823 26,455,352 March 31, 2019 December 31, 2018, As of March 31, 2019 December 31, 2018, March 31, 2019 December 31, 2018 Conversion of Deerfield Convertible Note 1,166,998 1,167,607 Conversion of 2021 Notes 4,481,182 4,481,182 Outstanding awards under equity incentive plans 5,117,655 3,704,755 Outstanding common stock warrants 2,527,763 2,527,763 Conversion of Series A Convertible Preferred Stock 1,112,334 1,112,334 Possible future issuances under equity incentive plans 293,586 648,272 Total common shares reserved for future issuance 14,699,518 13,641,913 Common Stock Activity The following table summarizes common stock activity for the three March 31, 2019: Shares of Common Stock Balance as of December 31, 2018 26,455,352 Common stock issued under Purchase Agreement 1,521,471 Balance as of March 31, 2019 27,976,823 In September 2018, 762,338 $4.9 March 31, 2019, not In October 2018, 8,333,334 3. Also in October 2018, 9,577 March 31, 2019, 6,240 2,080,000 Warrants During 2013, $3.8 “2013 1,079,453 2013 2013 1,079,453 2013 143,466 $5.85 2013 June 2, 2019, On June 2, 2014, 14,423,076 June 2, 2024, 1,923,077 $5.85 The Company determined that the 2013 2013 2013 In connection with a Collaboration and License Agreement (the “License Agreement”) with KVK Tech, Inc. (“KVK”), in October 2018, 500,000 $2.30 not four 125,000 500,000 October 24, 2023. may The Company determined that, since KVK qualifies as a customer under ASC 606, 815 815 606

Note G - Stock-based Compensati

Note G - Stock-based Compensation	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	G. Stock-Based Compensation The Company maintains a stock-based compensation plan (the “ Incentive Stock Plan”) that governs stock awards made to employees and directors prior to completion of the IPO. In November 2014, April 2015, 2014 “2014 April 2015. 2014 may 2014 5,076,694 March 31, 2019. 2014 January 1 January 1, 2016, January 1, 2024, 4% December 31 2014 January 1, 2019, 2014 1,058,214 During the three 31, 2019, no three 31, 2018 1,307 Stock-based compensation expense recorded under the Incentive Stock Plan and the 2014 Three months ended March 31, 2019 2018 Research and development $ 433 $ 376 General and administrative 857 905 Total stock-based compensation expense 1,290 1,281 There was no three March 31, 2019 2018 .

Note H - Fair Value of Financia

Note H - Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Fair Value Disclosures [Text Block]	H. Fair Value of Financial Instruments The accounting standard for fair value measurements provides a framework for measuring fair value and requires disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability. The Company uses a three three ● Level 1—Observable ● Level 2—Observable ● Level 3—Unobservable no The carrying amounts of certain financial instruments, including cash and cash equivalents, restricted cash and accounts payable and accrued expenses, approximate their respective fair values due to the short-term nature of such instruments. The fair value of the Deerfield Convertible Note was $6.4 $6.2 31, 2019 December 31, 2018. 2021 $52.8 $51.2 31, 2019 December 31, 2018. 2021 3 2021 31, 2019 December 31, 2018. Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made. The following table summarizes the conclusions reached regarding fair value measurements as of March 31, 2019 December 31, 2018 ( Balance as of March 31, 2019 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Deerfield Warrant liability $ 1,039 $ — $ — $ 1,039 Embedded Warrant Put Option 288 — — 288 Fundamental change and make-whole interest provisions embedded in 2021 Notes — — — — Deerfield Note Conversion Feature 94 — — 94 KVK Warrant liability 244 — 244 — Total liabilities $ 1,665 $ — $ 244 $ 1,421 Balance as of December 31, 2018 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Deerfield Warrant liability $ 1,557 $ — $ — $ 1,557 Embedded Warrant Put Option 154 — — 154 Fundamental change and make-whole interest provisions embedded in 2021 Notes — — — — Deerfield Note Conversion Feature 134 — — 134 KVK Warrant liability 273 — 273 — Total liabilities $ 2,118 $ — $ 273 $ 1,845 Trading securities: Certificates of deposit $ 246 $ 246 $ — $ — U.S. Treasury securities 3,014 3,014 — — Total assets $ 3,260 $ 3,260 $ — $ — The Company’s Deerfield Warrant liability, embedded Warrant Put Option, the fundamental change and the make-whole interest provisions embedded in the 2021 March 31, 2019 and December 31, 2018, 2021 31, 2018, 2021 March 31, 2019 and December 31, 2018. 2021 three March 31, 2019 and 2018 The Company’s KVK Warrant liability is measured at fair value on a recurring basis. As of March 31, 2019 December 31, 2018, no not not three March 31, 2019 not three March 31, 2018 October 2018. A reconciliation of the beginning and ending balances for the derivative and warrant liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3 Three months ended March 31, 2019 2018 Balance as of beginning of period $ 1,845 $ 7,709 Adjustment to fair value (424 ) 9,741 Balance as of end of period $ 1,421 $ 17,450

Note I - Net Loss Per Share

Note I - Net Loss Per Share	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Earnings Per Share [Text Block]	I. Net Loss Per Share Under the two No no two two Diluted net loss per share is the same as basic net loss per share for all periods presented because the effects of potentially dilutive items were anti-dilutive given the Company's net loss. The following securities, presented on a common stock equivalent basis, have been excluded from the calculation of weighted average number of shares of common stock outstanding because their effect is anti-dilutive: Three months ended March 31, 2019 2018 Warrants to purchase common stock 2,527,763 2,027,763 Awards under equity incentive plans 5,117,655 3,631,496 Deerfield Convertible Note 1,166,998 1,750,497 2021 Notes 4,481,182 5,040,914 Series A Convertible Preferred Stock 1,112,334 — Total securities excluded from the calculation of weighted average number of shares of common stock outstanding 14,405,932 12,450,670

Note J - Leases

Note J - Leases	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Lease Disclosure [Text Block]	J. Leases We have operating and finance leases for office space, laboratory facilities and various laboratory equipment, furniture and office equipment and leasehold improvements. Our leases have remaining lease terms of 1 7 5 1 The components of lease expense were as follows (in thousands): Three months ended March 31, Lease Cost 2019 Finance lease cost: Amortization of right-of-use assets $ 31 Interest on lease liabilities 11 Total finance lease cost 42 Operating lease cost 124 Short-term lease cost 57 Variable lease cost 15 Less: sublease income (25 ) Total lease costs $ 213 Supplemental cash flow information related to leases was as follows (in thousands): Three months ended March 31, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 11 Financing cash flows from finance leases 51 Operating cash flows from operating leases 108 Operating cash flows from short-term leases 57 Operating cash flows from variable lease costs 15 Right-of-use assets obtained in exchange for lease liabilities: Finance leases $ 737 Operating leases 1,852 Supplemental balance sheet information related to leases was as follows (in thousands, except weighted average remaining lease term and weighted average discount rate): March 31, 2019 Finance Leases Property and equipment, at cost $ 1,013 less: accumulated depreciation and amortization (306 ) Property and equipment, net $ 707 Other current liabilities 218 Other long-term liabilities 341 Total finance lease liabilities $ 559 Operating Leases Operating lease right-of-use assets $ 1,785 Current portion of operating lease liabilities 395 Operating lease liabilities, less current portion 2,142 Total operating lease liabilities $ 2,537 Weighted Average Remaining Lease Term Finance leases 3 years Operating leases 6 years Weighted Average Discount Rate Finance leases 7.7 % Operating leases 7.5 % Maturities of lease liabilities were as follows (in thousands): Finance Operating Year Ending December 31, Leases Leases 2019 (excluding the three months ended March 31, 2019) $ 191 $ 428 2020 251 499 2021 163 449 2022 11 461 2023 — 472 Thereafter — 903 Total lease payments $ 616 $ 3,212 Less: future interest expense (57 ) (675 ) Lease liabilities $ 559 $ 2,537

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its estimates, including those related to the useful lives of property and equipment, and assumptions used for purposes of determining stock-based compensation, income taxes, and the fair value of the derivative and warrant liability, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.
New Accounting Pronouncements, Policy [Policy Text Block]	Application of New or Revised Accounting Standards—Adopted From time to time, the Financial Accounting Standards Board (the “FASB”) or other standard-setting bodies issue accounting standards that are adopted by the Company as of the specified effective date. In April 2012, not In February 2016, 2016 02, Leases (Topic 842 ) 2016 02” January 1, 2019 not 12 not 2016 02 $2.6 January 1, 2019. In July 2017, 2017 11, Earnings Per Share (Topic 260 ), Distinguishing Liabilities from Equity (Topic 480 ), Derivatives and Hedging (Topic 815 ) – I. Accounting for Certain Financial Instruments with Down Round Features and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception 2017 11" 480 260. December 15, 2018, 2017 11 not In June 2018, 2018 07, Compensation – Stock Compensation (Topic 820 2018 07" 718, December 15, 2018, 718 718 718 2018 07 not Application of New or Revised Accounting Standards —Not In August 2018, 2018 13, Fair Value Measurement (Topic 820 2018 13" 820, Conceptual Framework for Financial Reporting—Chapter 8: August 28, 2018, December 15, 2019, 3 2018 13

Note F - Common Stock and War_2

Note F - Common Stock and Warrants (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Authorized Shares of Common Stock Reserved for Future Issuance [Table Text Block]	March 31, 2019 December 31, 2018 Conversion of Deerfield Convertible Note 1,166,998 1,167,607 Conversion of 2021 Notes 4,481,182 4,481,182 Outstanding awards under equity incentive plans 5,117,655 3,704,755 Outstanding common stock warrants 2,527,763 2,527,763 Conversion of Series A Convertible Preferred Stock 1,112,334 1,112,334 Possible future issuances under equity incentive plans 293,586 648,272 Total common shares reserved for future issuance 14,699,518 13,641,913
Schedule of Common Stock Outstanding Roll Forward [Table Text Block]	Shares of Common Stock Balance as of December 31, 2018 26,455,352 Common stock issued under Purchase Agreement 1,521,471 Balance as of March 31, 2019 27,976,823

Note G - Stock-based Compensa_2

Note G - Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three months ended March 31, 2019 2018 Research and development $ 433 $ 376 General and administrative 857 905 Total stock-based compensation expense 1,290 1,281

Note H - Fair Value of Financ_2

Note H - Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Balance as of March 31, 2019 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Deerfield Warrant liability $ 1,039 $ — $ — $ 1,039 Embedded Warrant Put Option 288 — — 288 Fundamental change and make-whole interest provisions embedded in 2021 Notes — — — — Deerfield Note Conversion Feature 94 — — 94 KVK Warrant liability 244 — 244 — Total liabilities $ 1,665 $ — $ 244 $ 1,421 Balance as of December 31, 2018 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Deerfield Warrant liability $ 1,557 $ — $ — $ 1,557 Embedded Warrant Put Option 154 — — 154 Fundamental change and make-whole interest provisions embedded in 2021 Notes — — — — Deerfield Note Conversion Feature 134 — — 134 KVK Warrant liability 273 — 273 — Total liabilities $ 2,118 $ — $ 273 $ 1,845 Trading securities: Certificates of deposit $ 246 $ 246 $ — $ — U.S. Treasury securities 3,014 3,014 — — Total assets $ 3,260 $ 3,260 $ — $ —
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Three months ended March 31, 2019 2018 Balance as of beginning of period $ 1,845 $ 7,709 Adjustment to fair value (424 ) 9,741 Balance as of end of period $ 1,421 $ 17,450

Note I - Net Loss Per Share (Ta

Note I - Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three months ended March 31, 2019 2018 Warrants to purchase common stock 2,527,763 2,027,763 Awards under equity incentive plans 5,117,655 3,631,496 Deerfield Convertible Note 1,166,998 1,750,497 2021 Notes 4,481,182 5,040,914 Series A Convertible Preferred Stock 1,112,334 — Total securities excluded from the calculation of weighted average number of shares of common stock outstanding 14,405,932 12,450,670

Note J - Leases (Tables)

Note J - Leases (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Lease, Cost [Table Text Block]	Three months ended March 31, Lease Cost 2019 Finance lease cost: Amortization of right-of-use assets $ 31 Interest on lease liabilities 11 Total finance lease cost 42 Operating lease cost 124 Short-term lease cost 57 Variable lease cost 15 Less: sublease income (25 ) Total lease costs $ 213
Schedule of Leases Cash Flow Information [Table Text Block]	Three months ended March 31, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from finance leases $ 11 Financing cash flows from finance leases 51 Operating cash flows from operating leases 108 Operating cash flows from short-term leases 57 Operating cash flows from variable lease costs 15 Right-of-use assets obtained in exchange for lease liabilities: Finance leases $ 737 Operating leases 1,852
Schedule of Leases Balance Sheet Information [Table Text Block]	March 31, 2019 Finance Leases Property and equipment, at cost $ 1,013 less: accumulated depreciation and amortization (306 ) Property and equipment, net $ 707 Other current liabilities 218 Other long-term liabilities 341 Total finance lease liabilities $ 559 Operating Leases Operating lease right-of-use assets $ 1,785 Current portion of operating lease liabilities 395 Operating lease liabilities, less current portion 2,142 Total operating lease liabilities $ 2,537 Weighted Average Remaining Lease Term Finance leases 3 years Operating leases 6 years Weighted Average Discount Rate Finance leases 7.7 % Operating leases 7.5 %
Operating and Finance Lease, Liability, Maturity [Table Text Block]	Finance Operating Year Ending December 31, Leases Leases 2019 (excluding the three months ended March 31, 2019) $ 191 $ 428 2020 251 499 2021 163 449 2022 11 461 2023 — 472 Thereafter — 903 Total lease payments $ 616 $ 3,212 Less: future interest expense (57 ) (675 ) Lease liabilities $ 559 $ 2,537

Note A - Description of Busin_2

Note A - Description of Business and Basis of Presentation (Details Textual) - USD ($)	Feb. 28, 2019	Oct. 10, 2018	Oct. 05, 2018	Mar. 31, 2019	Sep. 04, 2018	Dec. 31, 2018
Sale of Securities, Value, Available to Issue						$ 150,000,000
Sale of Securities Covered Under Prospectus Supplement, Value, Anticipated Amount to Be Sold Under Registration Statement						18,500,000
Sale of Securities Covered Under Prospectus Supplement, Value, Anticipated Sales Under Purchase Agreement						$ 15,300,000
Sale of Securities Covered Under Prospectus Supplement, Value, Anticipated Sales Under ATM Agreement				$ 3,200,000
Cowen and Company, LLC [Member]
Stock Issued During Period, Shares, New Issues					762,338
Proceeds from Issuance of Common Stock					$ 4,900,000
Sale of Stock, Commission Fee					3.00%
RBC Capital Markets, LLC [Member]
Sale of Stock, Authorized Offering Price					$ 50,000,000
Lincoln Park [Member]
Sale of Securities, Value, Available to Issue	$ 15,000,000
Stock Issued During Period, Shares, New Issues				1,401,271,000,000
Proceeds from Issuance of Common Stock				$ 2,700,000
Purchase Agreement, Term	3 years
Purchase Agreement, Additional Shares to Be Issued as Commitment Shares	120,200
First ATM Agreement [Member]
Stock Issued During Period, Shares, New Issues				1,401,271,000,000
Proceeds from Issuance of Common Stock				$ 2,700,000
Second ATM Agreement [Member]
Stock Issued During Period, Shares, New Issues				0
Second ATM Agreement [Member] | RBC Capital Markets, LLC [Member]
Sale of Stock, Commission Fee					3.00%
Second ATM Agreement [Member] | RBC Capital Markets, LLC [Member] | Maximum [Member]
Sale of Stock, Authorized Offering Price					$ 50,000,000
Underwriting Agreement [Member] | RBC Capital Markets, LLC [Member]
Stock Issued During Period, Shares, New Issues		8,333,334	8,333,334
Shares Issued, Price Per Share		$ 3
Proceeds from Issuance of Common Stock, Net		$ 23,100,000

Note B - Summary of Significa_2

Note B - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Operating Lease, Liability, Total	$ 2,537
Operating Lease, Right-of-Use Asset	$ 1,785
Accounting Standards Update 2016-02 [Member]
Operating Lease, Liability, Total		$ 2,600
Operating Lease, Right-of-Use Asset		$ 2,600

Note C - Debt Obligations (Deta

Note C - Debt Obligations (Details Textual) - USD ($)	Oct. 05, 2018	Jun. 11, 2018	Feb. 09, 2016	Jun. 02, 2014	Mar. 31, 2019	Mar. 31, 2018	Nov. 20, 2018	Jun. 30, 2016
Interest Paid, Excluding Capitalized Interest, Operating Activities					$ 2,287,000	$ 2,618,000
Conversion from Deerfield Convertible Note to Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued		598,568
Debt Conversion, Original Debt, Amount		$ 3,333,333
Debt Conversion, Accrued Interest		$ 168,288
Exchanged 2021 Notes for Series A Preferred Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued	9,577
Debt Conversion, Original Debt, Amount	$ 9,577,000
Interest Paid, Excluding Capitalized Interest, Operating Activities	95,105
Debt Conversion, Expenses, Reimbursement	$ 25,000
Preferred Stock, Aggregate Stated Value Per Share	$ 1,000
Convertible Notes 2021 [Member]
Beneficial Ownership, Cap Limit, Percentage							9.985%
Deerfield Convertible Notes [Member]
Beneficial Ownership, Cap Limit, Percentage							4.985%
Series A Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	0.0001		$ 0.0001
Preferred Stock, Aggregate Stated Value Per Share	1,000
Convertible Preferred Stock, Conversion Price	$ 3
Convertible Preferred Stock, Shares Issuable Upon Conversion	3,192,334				1,112,334
Convertible Preferred Stock, Conversion Restriction, Percentage of Common Stock	4.985%
2021 Notes [Member]
Debt Instrument, Convertible, Conversion Price			$ 17.11
Debt Instrument, Face Amount			$ 86,300,000
Debt Instrument, Interest Rate, Stated Percentage			5.50%
Proceeds from Debt, Net of Issuance Costs			$ 82,800,000
Repayments of Long-term Debt, Total			18,600,000
Debt Instrument, Sinking Fund Payment			$ 0
Debt Conversion, Converted Instrument, Shares Issued			58.4454
Debt Conversion, Original Debt, Amount			$ 1,000
Debt Instrument Repurchase Price Equal to Percentage of Principal Amount			100.00%
Deerfield Facility Agreement [Member]
Line of Credit Facility, Maximum Borrowing Capacity				$ 60,000,000
Line of Credit Facility, Interest Rate at Period End				9.75%
Debt Covenant, Debt Financing Restriction				$ 750,000
Deerfield Facility Agreement [Member] | Deerfield Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.78
Deerfield Facility Agreement [Member] | Deerfield Warrant [Member] | IPO [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				1,923,077
Deerfield Facility Agreement [Member] | Series D Redeemable Convertible Preferred Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				14,423,076
Own-share Lending Arrangement, Shares, Issued				1,923,077
Mandatorily Redeemable Preferred Stock, Fair Value Disclosure				$ 1,500,000
Deerfield Facility Agreement [Member] | Initial Public Offering [Member]
Reclassification of Common Stock Shares				256,410
Deerfield Facility Agreement [Member] | Term Notes [Member]
Proceeds from Secured Notes Payable				$ 15,000,000
Deerfield Facility Agreement [Member] | Deerfield Convertible Notes [Member]
Proceeds from Secured Notes Payable				$ 10,000,000
Debt Instrument, Convertible, Conversion Price				$ 5.85
Third Line of Credit Agreement [Member] | City National Bank of Florida [Member]
Line of Credit Facility, Maximum Borrowing Capacity								$ 1,100,000

Note D - Commitments and Cont_2

Note D - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Loss Contingency Accrual, Ending Balance	$ 0	$ 0

Note E - Preferred Stock and _2

Note E - Preferred Stock and Warrants (Details Textual) - $ / shares	Oct. 05, 2018	Mar. 31, 2019	Dec. 31, 2018	Feb. 09, 2016
Preferred Stock, Shares Authorized		10,000,000
Preferred Stock, Shares Issued, Total		9,577
Preferred Stock, Shares Outstanding, Ending Balance		3,337	3,337
Exchanged 2021 Notes for Series A Preferred Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued	9,577
Preferred Stock, Aggregate Stated Value Per Share	$ 1,000
Series A Preferred Stock [Member]
Preferred Stock, Shares Authorized		9,578
Preferred Stock, Shares Outstanding, Ending Balance		3,337
Preferred Stock, Aggregate Stated Value Per Share	1,000
Convertible Preferred Stock, Conversion Price	$ 3
Convertible Preferred Stock, Shares Issuable Upon Conversion	3,192,334	1,112,334
Convertible Preferred Stock, Conversion Restriction, Percentage of Common Stock	4.985%
Preferred Stock, Par or Stated Value Per Share	$ 0.0001			$ 0.0001
Conversion of Stock, Shares Converted		6,240
Conversion of Stock, Shares Issued		2,080,000

Note F - Common Stock and War_3

Note F - Common Stock and Warrants (Details Textual) - USD ($)	Oct. 25, 2018	Oct. 10, 2018	Oct. 05, 2018	Jun. 02, 2014	Mar. 31, 2019	Dec. 31, 2013	Sep. 04, 2018	Dec. 31, 2018
Common Stock, Shares, Issued, Total					27,976,823			26,455,352
Common Stock, Shares Authorized					250,000,000			250,000,000
Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						143,466
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 5.85
2013 Warrants [Member]
Debt Instrument, Face Amount						$ 3,800,000
Class of Warrant or Right Issued						1,079,453
Series D Redeemable Convertible Preferred Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights						1,079,453
Deerfield Warrant [Member]
Class of Warrant or Right Issued				14,423,076
Deerfield Warrant [Member] | Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				1,923,077
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 5.85
Warrant Issued to KVK [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.30
Class of Warrant or Right, Additional Shares Exercisable for Each Milestones	125,000
Series A Preferred Stock Converted Into Common Stock [Member]
Conversion of Stock, Shares Converted					6,240
Conversion of Stock, Shares Issued					2,080,000
Exchanged 2021 Notes for Series A Preferred Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued			9,577
Second ATM Agreement [Member]
Stock Issued During Period, Shares, New Issues					0
Cowen and Company, LLC [Member]
Stock Issued During Period, Shares, New Issues							762,338
Proceeds from Issuance of Common Stock							$ 4,900,000
RBC Capital Markets, LLC [Member] | Underwriting Agreement [Member]
Stock Issued During Period, Shares, New Issues		8,333,334	8,333,334

Note F - Common Stock and War_4

Note F - Common Stock and Warrants - Reserved Authorized Shares of Common Stock for Future Issuance (Details) - shares	Mar. 31, 2019	Dec. 31, 2018
Common shares reserved for future issuance (in shares)	14,699,518	13,641,913
Series A Convertible Preferred Stock [Member]
Common shares reserved for future issuance (in shares)	1,112,334	1,112,334
Warrant [Member]
Common shares reserved for future issuance (in shares)	2,527,763	2,527,763
Share-based Payment Arrangement [Member]
Common shares reserved for future issuance (in shares)	5,117,655	3,704,755
Possible Future Issuances Under Equity Incentive Plans [Member]
Common shares reserved for future issuance (in shares)	293,586	648,272
2021 Notes [Member]
Common shares reserved for future issuance (in shares)	4,481,182	4,481,182
Convertible Notes Payable [Member]
Common shares reserved for future issuance (in shares)	1,166,998	1,167,607

Note F - Common Stock and War_5

Note F - Common Stock and Warrants - Common Stock Activity (Details)	3 Months Ended
	Mar. 31, 2019shares
Balance (in shares)	26,455,352
Balance (in shares)	27,976,823
Equity Line of Credit [Member]
Common stock issued under Purchase Agreement (in shares)	1,521,471

Note G - Stock-based Compensa_3

Note G - Stock-based Compensation (Details Textual) - USD ($) $ in Thousands	Jan. 01, 2019	Mar. 31, 2019	Mar. 31, 2018
Increase in Common Stock Reserved for Issuance	1,058,214
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		0	1,307
Share-based Payment Arrangement, Expense		$ 1,290	$ 1,281
Performance Shares [Member]
Share-based Payment Arrangement, Expense		$ 0	$ 0
2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		5,076,694
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Reserved for Issuance, Incremental Percentage of Capital Stock Outstanding		4.00%

Note G - Stock-based Compensa_4

Note G - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Stock based compensation expense	$ 1,290	$ 1,281
Research and Development Expense [Member]
Stock based compensation expense	433	376
General and Administrative Expense [Member]
Stock based compensation expense	$ 857	$ 905

Note H - Fair Value of Financ_3

Note H - Fair Value of Financial Instruments (Details Textual) - Fair Value, Inputs, Level 3 [Member] - Deerfield Facility Agreement [Member] - USD ($) $ in Millions	Mar. 31, 2019	Dec. 31, 2018
Deerfield Convertible Notes [Member]
Long-term Debt, Fair Value	$ 6.4	$ 6.2
Term Notes [Member]
Long-term Debt, Fair Value	$ 52.8	$ 51.2

Note H - Fair Value of Financ_4

Note H - Fair Value of Financial Instruments - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Financial liabilities measured at fair value on recurring basis	$ 1,665	$ 2,118
Financial assets measured at fair value on recurring basis		3,260
Certificates of Deposit [Member]
Financial assets measured at fair value on recurring basis		246
US Treasury Securities [Member]
Financial assets measured at fair value on recurring basis		3,014
Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis
Financial assets measured at fair value on recurring basis		3,260
Fair Value, Inputs, Level 1 [Member] | Certificates of Deposit [Member]
Financial assets measured at fair value on recurring basis		246
Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member]
Financial assets measured at fair value on recurring basis		3,014
Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis	244	273
Financial assets measured at fair value on recurring basis
Fair Value, Inputs, Level 2 [Member] | Certificates of Deposit [Member]
Financial assets measured at fair value on recurring basis
Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member]
Financial assets measured at fair value on recurring basis
Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis	1,421	1,845
Financial assets measured at fair value on recurring basis
Fair Value, Inputs, Level 3 [Member] | Certificates of Deposit [Member]
Financial assets measured at fair value on recurring basis
Fair Value, Inputs, Level 3 [Member] | US Treasury Securities [Member]
Financial assets measured at fair value on recurring basis
Deerfield Warrant Liability [Member]
Financial liabilities measured at fair value on recurring basis	1,039	1,557
Deerfield Warrant Liability [Member] | Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis
Deerfield Warrant Liability [Member] | Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis
Deerfield Warrant Liability [Member] | Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis	1,039	1,557
Embedded Put Option [Member]
Financial liabilities measured at fair value on recurring basis	288	154
Embedded Put Option [Member] | Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis
Embedded Put Option [Member] | Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis
Embedded Put Option [Member] | Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis	288	154
Fundamental Change and Make-Whole Interest Provisions Embedded in 2021 Notes [Member]
Financial liabilities measured at fair value on recurring basis
Fundamental Change and Make-Whole Interest Provisions Embedded in 2021 Notes [Member] | Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis
Fundamental Change and Make-Whole Interest Provisions Embedded in 2021 Notes [Member] | Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis
Fundamental Change and Make-Whole Interest Provisions Embedded in 2021 Notes [Member] | Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis
Embedded Deerfield Note Put Option [Member]
Financial liabilities measured at fair value on recurring basis	94	134
Embedded Deerfield Note Put Option [Member] | Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis
Embedded Deerfield Note Put Option [Member] | Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis
Embedded Deerfield Note Put Option [Member] | Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis	94	134
KVK Warrant Liability [Member]
Financial liabilities measured at fair value on recurring basis	244	273
KVK Warrant Liability [Member] | Fair Value, Inputs, Level 1 [Member]
Financial liabilities measured at fair value on recurring basis
KVK Warrant Liability [Member] | Fair Value, Inputs, Level 2 [Member]
Financial liabilities measured at fair value on recurring basis	244	273
KVK Warrant Liability [Member] | Fair Value, Inputs, Level 3 [Member]
Financial liabilities measured at fair value on recurring basis

Note H - Fair Value of Financ_5

Note H - Fair Value of Financial Instruments - Reconciliation of Beginning and Ending Balances for Derivative and Warrant Liability Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Balance as of beginning of period	$ 1,845	$ 7,709
Adjustment to fair value	(424)	9,741
Balance as of end of period	$ 1,421	$ 17,450

Note I - Net Loss Per Share - A

Note I - Net Loss Per Share - Anti-dilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Antidilutive securities (in shares)	14,405,932	12,450,670
Warrants to Purchase Common Stock [Member]
Antidilutive securities (in shares)	2,527,763	2,027,763
Share-based Payment Arrangement [Member]
Antidilutive securities (in shares)	5,117,655	3,631,496
Convertible Debt Securities [Member]
Antidilutive securities (in shares)	1,166,998	1,750,497
2021 Notes [Member]
Antidilutive securities (in shares)	4,481,182	5,040,914
Series A Convertible Preferred Stock [Member]
Antidilutive securities (in shares)	1,112,334

Note J - Leases (Details Textua

Note J - Leases (Details Textual)	3 Months Ended
	Mar. 31, 2019
Lessee, Lease, Option to Extend, Maximum Term	5 years
Lessee, Lease, Option to Terminate, Term	1 year
Minimum [Member]
Lessee, Lease, Remaining Term of Contract	1 year
Maximum [Member]
Lessee, Lease, Remaining Term of Contract	7 years

Note J - Leases - Lease Cost (D

Note J - Leases - Lease Cost (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Amortization of right-of-use assets	$ 31
Interest on lease liabilities	11
Total finance lease cost	42
Operating lease cost	124
Short-term lease cost	57
Variable lease cost	15
Less: sublease income	(25)
Total lease costs	$ 213

Note J - Leases - Supplement Ca

Note J - Leases - Supplement Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Operating cash flows from finance leases	$ 11
Financing cash flows from finance leases	51
Operating cash flows from operating leases	108
Operating cash flows from short-term leases	57
Operating cash flows from variable lease costs	15
Finance leases	737
Operating leases	$ 1,852

Note J - Leases - Supplement Ba

Note J - Leases - Supplement Balance Sheet Information Related to Lease (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
less: accumulated depreciation and amortization	$ (31)
Lease liabilities	559
Operating lease right-of-use assets	1,785
Current portion of operating lease liabilities	395
Operating lease liabilities, less current portion	2,142
Total operating lease liabilities	$ 2,537
Finance leases (Year)	3 years
Operating leases (Year)	6 years
Finance leases	7.70%
Operating leases	7.50%
Property and Equipment, At Cost [Member]
Property and equipment, at cost	$ 1,013
Accumulated Depreciation and Amortization [Member]
less: accumulated depreciation and amortization	(306)
Property and Equipment, Net [Member]
Property and equipment, net	707
Other Current Liabilities [Member]
Other current liabilities	218
Other Noncurrent Liabilities [Member]
Other long-term liabilities	341
Operating Lease Right-of-Use Assets [Member]
Operating lease right-of-use assets	1,785
Current Portion of Operating Lease Liabilities [Member]
Current portion of operating lease liabilities	395
Operating Lease Liabilities, Less Current Portion [Member]
Operating lease liabilities, less current portion	$ 2,142

Note J - Leases - Maturities of

Note J - Leases - Maturities of lease Liabilities (Details) $ in Thousands	Mar. 31, 2019USD ($)
2019 (excluding the three months ended March 31, 2019)	$ 191
2019 (excluding the three months ended March 31, 2019)	428
2020	251
2020	499
2021	163
2021	449
2022	11
2022	461
2023
2023	472
Thereafter
Thereafter	903
Total lease payments	616
Total lease payments	3,212
Less: future interest expense	(57)
Less: future interest expense	(675)
Lease liabilities	559
Operating Lease, Liability, Total	$ 2,537